ARTICLE | Finance
Qiming looks to tap China’s public biotech boom
With Fidelity veteran Jane Wu as CIO, firm launches $500M hedge fund to invest in public equities
July 21, 2021 2:02 AM UTC
Updated on Jul 24, 2021 at 1:03 AM UTC
Qiming is joining other high-profile investors in China’s burgeoning healthcare sector by launching its first vehicle to invest in public equities with more than $500 million, sources familiar with the matter told BioCentury.
Springhill Fund will initially focus on investing in public companies in Greater China and elsewhere in Asia, one of the sources said, adding that the “fund aims to be long biased with concentrated long-term holdings.” It will invest across healthcare subsectors...